Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT06062498
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, due to the varied nature of the disease, development of resistance to this therapeutic approach is very common in the metastatic setting. The purpose of this study is to see whether the effectiveness of elacestrant can be enhanced by combining it with a targeted agent such as a CDK4/6 inhibitor to treat patients with ER+/HER2- or metastatic breast cancer with prior exposure to a CDK4/6 inhibitor.

Key Dates

First listed
Oct 2, 2023
Start date
Sep 29, 2023
Status verified
Jun 2026
Primary completion
Jul 1, 2028
Completion
Jul 1, 2029

Study Design

Enrollment
174 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Elacestrant Monotherapy
    Elacestrant (345 mg) will be taken orally once daily for each 28-day cycle. Courses repeat until progressive disease.
  • Experimental: Combination Therapy
    Patients will receive either: Elacestrant 345 mg orally once daily \+ Palbociclib 125 mg orally once daily for 21 days out of 28-day cycle OR Abemaciclib 150 mg orally twice daily OR Ribociclib 600 mg orally once daily for 21 days out of 28-day cycle

Primary Outcome Measure

Progression-Free Survival (PFS) [ Time Frame: Up to 5 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Northwestern UniversityChicagoIllinois60611
William Gradishar, MD
[email protected]
312-695-6180
William Gradishar, MD (PRINCIPAL_INVESTIGATOR)
Rush University Medical CenterChicagoIllinois60612
Ruta D Rao, MD
[email protected]
(312) 942-5904
University of ChicagoChicagoIllinois60637
Nan Chen, MD
[email protected]
(773) 702-6149

Find similar trials in Chicago, IL

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Northwestern University· Chicago, ILRush University Medical Center· Chicago, ILUniversity of Chicago· Chicago, IL

Related Studies